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Analytical and Clinical Performance of Improved Abbott IMx CA 125 Assay: 
Comparison with Abbott CA 125 RIA
Chris M.G. Thomas,1,2,5 Leon F.A.G. Massuger,1 Martin F.G. Segers,2 Charles P.T. Schijf,1 Wim H. Doesburg,3 and Theo Wobbes4
We compared the improved Abbott IMx cancer antigen including most of the clinical studies mentioned above,
(CA) 125 assay (cat. no. 7A89) with the Abbott CA 125 have been performed with the first commercially avail-
RIA. Serum specimens were from healthy perimeno- able one-step IRMA (<3) developed by Centocor (Malvern,
pausal women (n = 124) and from patients with benign PA) in which 125I-labeled antibody to CA 125 is used as a
gynecologic and nongynecologic diseases (n 124), tracer. Subsequently, three other assay test kits involv­
ing 125I-labeled OC 125 and five other immunoassayovarian carcinoma (n = 104), or other malignancies (n
193). The IMx assay detected as little as 0.193 kAU/L CA procedures involving enzyme-labeled OC 125 have been
125 (AU = arbitrary Abbott unit), demonstrated up to developed.
29% overestimation upon serum dilution, low within- We have previously reported the analytical perfor-
assay (2.7-5.6%) and between-assay (4.8-8.2% ) CVs, mance and comparability of five of the available CA
and no high-dose hook effect ^46 000 kAU/L nor influ- 125 assay kits (9). Emphasis was given to method
ence from human anti-mouse antibodies in serum of comparison analysis with orthogonal regression and to
women injected with OC 125 F(ab')2. Values by IMx were comparison of concordance and discordance of assay
20% lower than by RIA for healthy peri menopausal results of each kit on the basis of cutoff concentrations
women (n = 100; IMx = 0.80 RIA -  2.5 kAU/L), and at of 35 and 65 kAU/L (the arbitrary unit is related to an
least 50% higher for those with benign or malignant Abbott-maintained reference preparation; no interna-
ovarian disorders at concentrations <100 kAU/L. Receiv- tionally recognized standard is available at this time),
er-operating characteristic (ROC) curve analysis of ovar- The present study details the performance character-
ian neoplasma vs perimenopausal controls indicated a istics and clinical usefulness of the fully automated and
gain of specificity and sensitivity with the improved IMx improved IMx CA 125 procedure (Abbott Laboratories,
assay over the RIA, but ROC performance was the same North Chicago, IL). We have correlated CA 125 values
with either assay if patients with benign ovarian disorders obtained with the recalibrated and reformulated IMx
were used as controls. assay and those obtained with the Abbott CA 125 RIA.
Furthermore, this report attempts to discern (a)
Indexing Terms: ovarian cancer/tumor markers/ 'intermethod com- whether the recalibration provides good agreement of
parison/ heterophiie antibodies cutoff (35 and 65 kAU/L) with the Abbott RIA; (6)
whether improved assay sensitivity and precision pro-
A variety of monoclonal antibodies has been generated vides better distinction between patients with and
against antigens associated with a broad range of malig- without ovarian cancer; and (c) whether the combined
nancies (1). The anti-cancer antigen (CA) 125 monoclonal application of polyclonal sheep anti-CA 125 antibody
antibody (OC 125) has been used to develop a serodiag- on microparticles and the OC 125 monoclonal antibody 
nostic immunometric sandwich-type assay (IRMA) for 
ovarian carcinoma (2, 3 ).6 The specificity and the sensi-
conjugated to alkaline phosphatase in the improved 
IMx assay further protects against falsely increased 
tivity of the CA 125 assay have been sufficient to support test results due to heterophiie (human anti-mouse) 
its evaluation in several clinical applications for use with antibodies (HAMA) in the serum specimens.
ovarian cancer patients, including detection of disease 
prior to second-look surgery (4 ,5  ), monitoring response to 
therapy (6), differential diagnosis (7), and even early 
detection of ovarian carcinoma (8). Thus, increased con- say (cat. no. 7A89) is based on the microparticle en- 
centrations of CA 125 in serum are thought to indicate zyme immunoassay (MEIA) technology developed for
Materials and Methods
Description of immunoassays. The IMx CA 125 as-
the presence of disease. Many of these measurements,
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the Abbott IMx automated immunoassay system. Cur­
rently, the IMx CA 125 assay is not available for sale in 
the US. The probe/electrode assembly delivers 150 /xL 
of serum sample, specimen diluent (buffered sheep 
serum with protein stabilizers), and anti-CA 125 
(sheep, polyclonal) antibody-coated microparticles in 
buffer to the incubation well of the reaction cell. After 
formation of antibody-antigen complex during incuba­
tion, an aliquot is transferred to the glass fiber matrix 
to which the microparticles are irreversibly bound, and 
the matrix is washed to remove unbound materials.
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The OC 125 (mouse, monoclonal)—alkaline phos­
phatase conjugate in buffer (>0.1 mg/L) is dispensed 
onto the matrix to bind to the antibody-antigen com­
plex. After another wash, 4-methylumbelliferyl phos­
phate substrate (1.2 mmol/L in buffer) is added to the 
matrix and the fluorescent product is measured by the 
MEIA optical assembly. Total procedure time is 42 
min. Specimens with a CA 125 assay value >600 
kAU/L are automatically flagged with the code “>600.” 
In this case, a manual dilution procedure of the speci­
men can be performed with the IMx CA 125 specimen 
diluent before pipetting the sample into the sample
well. Six IMx CA 125 calibrators (0, 15, 50, 125, 375, 
and 600 kAU/L) are processed, and the point-to-point 
curve calculated by the built-in algorithm is stored. A 
Mode 1 calibrator of 50 kAU/L for system calibration 
verification and curve adjustment within the manufac­
turer’s specified preset limits is run with each series of24 tests.
The IMx CA 125 assay has recently been improved 
by recalibration and reformulation. To more closely 
match the Centocor RIA and RIA II assays and allow 
for full market entry, Abbott has adjusted the CA 125 
assay standards (~35%), increased the protein concen­
trations of accessory and specimen diluents, and im­
proved the manufacturing process of the micropar­
ticles .
The Abbott CA 125 RIA Monoclonal is a double­
determinant one-step sandwich-type IRMA identical to 
the Centocor CA 125 RIA procedure serving as the 
comparison method. This kit includes the monoclonal 
OC 125 antibody both as capture and tracer in a 
simultaneous sandwich format (3). According to the 
manufacturer’s instructions, 100-/xL aliquots of five CA 
125 calibrators (range 7-500 kAU/L) or 100 fiL of
serum specimen are pipetted into tubes and incubated 
for 20 h at room temperature, together with OC 125- 
coated beads and 125I-labeled OC 125. After the beads 
are washed to remove unbound materials, the radioac­tivity bound to the coated carriers, which is propor­
tional to the concentration of CA 125 in the serum 
specimen, is counted in a gamma counter. Results of 
this assay were calculated with the 1224 MultiCalc 
Program (Wallac Oy, Turku, Finland). The minimum 
detectable concentration of this test is —7.0 kAU/L.
Analytical evaluation. The performance of the IMx 
CA 125 MEIA was assessed by evaluating (a) the detection limit of the assay (defined as the lowest 
concentration of CA 125 that is >2 SD above the mean 
signal for 20 replicate determinations of the zero cali­
brator); (b) within-assay precision (three serum speci­
mens with CA 125 concentrations 17-240 kAU/L in 20 
replicates assayed three times) and between-assay pre­
cision (the same serum specimens run in duplicate in 
73-79 consecutive assays run over >90 days), as well 
as construction of a precision profile (covering the 
entire dynamic range of both assay procedures and 
derived from the duplicate measurements of unknowns 
processed during the present study); and (c) accuracy 
testing, comprising checks of linearity and influence of
supplied specimen diluent buffer (determined with 
three serially diluted serum specimens with high CA 
125 concentrations); tests of the occurrence of a high- 
dose hook effect (defined as an analytical response 
below that of the highest calibrator of 600 kAU/L, in 
two undiluted specimens with a very high concentra­
tion of CA 125); and assessment of CA 125 measure­
ments made with IMx and RIA in serum specimens 
from three ovarian cancer patients for possible inter­
ference from HAMA before and after OC125 F(ab')2
injection (10).
Study material. The clinical evaluation material 
comprised serum samples from healthy perimeno- 
pausal women all with echoscopically normal ovaries (n 
= 124, median age 48 years, range 40-63) serving as 
controls, and serum specimens collected from pretreat­
ment patients with benign gynecologic (n = 91, median 
age 41 years, range 14-77) and nongynecologic dis­
eases (n = 33, median age 57 years, range 28-92); 
patients with ovarian carcinoma (n = 104, median age 
54 years, range 17—81); and during follow-up of 8 
patients with recurrent disease (n = 71), or other 
gynecologic (n = 81, median age 60 years, range 25-85) 
and nongynecologic (gastrointestinal) malignancies (n 
= 112, median age 65 years, range 32-86). The pa­
tients with ovarian neoplasms were staged according to 
recommendations of the International Federation of 
Gynaecology & Obstetrics (FIGO) (11) and those with 
gastrointestinal malignancies according to criteria of 
the International Union Against Cancer (12). All the 
serum samples were collected by venipuncture and 
kept frozen at -35°C until assay. The procedures 
followed were in accordance with the Helsinki Decla­
ration of 1975, as revised in 1983.
Statistics. From the CA 125 results for both tests we 
calculated frequency distributions of the healthy con­
trols. For all the groups of clinical serum specimens 
examined we indicated the median, minimum, and 
maximum serum concentrations and calculated the 
percentages of CA 125 values that exceeded cutoff 
values of 35 and 65 kAU/L. The results obtained from 
healthy controls and those with benign ovarian disease 
and ovarian cancer were compared by linear regression 
analysis (13). To extend the comparison of methods, we 
also calculated the linear regressions of the two assays 
in eight follow-up cases of ovarian cancer patients. 
Diagnostic test performance was further evaluated by 
documenting the diagnostic accuracy of each test with 
receiver-operating characteristic (ROC) curves and cal­
culation of the areas under these curves (AUC) (14).
Results
Analytical Evaluation
Sensitivity. The minimum detectable concentration 
of the IMx CA 125 assay was 0.193 kAU/L (mean +2 
SD), on the basis of 20 replicate measurements of the 
zero calibrator (mean 0.049, SD 0.072 kAU/L).
Linearity. The recoveries of three human serum 
specimens (mean concentrations 413, 451, and 399
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Table 1. Dilution linearity of the Abbott IMx
CA 125 assay.
Serum sample
1 2 3
CA 125, kAU/L 413 451 399
Recovery, %a
No dilution 100 100 100
Twofold dild. 106 105 109
Fourfold dild. 115 110 119
Eightfold dild. 117 120 127
16-fold dild. 123 129 121
a Recovery = (CA 125 measured/expected) x 100.
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kAU/L) serially diluted 2-, 4-, 8-, and 16-fold increased 
progressively, ranging between 105% and 129% of the 
undiluted concentrations (Table 1). Unlike the GA 125 
RIA, the IMx CA 125 assay did not show a high-dose hook effect up to 46 000 kAU/L, as demonstrated by 
two specimens.
Precision. Within-assay precision of the IMx assay 
was tested with three human serum specimens at CA 
125 concentrations of ~19, 40, and 230 kAU/L. Repli­
cates of 20 in each of three different assay runs re­
vealed mean CVs ranging from 3.2% to 4.8%. To 
calculate the between-assay precision, we also assayed 
these serum specimens in 79 consecutive runs over 
>90 days. The resulting mean CVs ranged from 5.8% to 
8.2%.
Figure 1 depicts the precision profiles of the IMx 
procedure and the RIA test. The first four ranges of CA 
125 concentrations <35 kAU/L (0-3.5, 3.5-7.0, 7.0-15, 
and 15-35 kAU/L) showed CVs that decreased from 
16% to 4.6% with the IMx, and, because of the detection 
limit of the RIA (>7.0 kAU/L), from 49% to 23% 
between 7.0 and 35 kAU/L if measured by RIA. The 
reproducibility of the IMx procedure for the remaining 
part of the dynamic range of the test (35-600 kAU/L) 
was always much lower (range 2.3-3.6%) than that 
obtained with the RIA procedure (range 6.1-9.8%).
Method comparison of immunoassay procedures. 
Fig. 2 shows the linear relations between the results 
obtained with the CA 125 IMx and RIA over the 
studied range of CA 125 concentrations (>7.0-23 000 
kAU/L). Almost identical slopes were calculated for the
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Fig. 1. CA 125 precision profiles of improved IMx and RIA.
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Fig. 2. Correlation plots of CA 125 measurements by Abbott IMx 
and RIA In serum of healthy women and patients with benign or 
malignant ovarian diseases for concentration ranges (A) >7.0-44 
kAU/L (controls, y = 0.80x - 2.5; benign ovarian disease, y = 1.50x 
■- 9.5; ovarian cancer, /  = 1.67/ -  13); (S) >35-100 kAU/L (benign 
ovarian disease, y -* 3,37x - 112; ovarian cancer, y ~~ 2.45x •• 72); 
or (C) >100-23 000 kAU/L (benign ovarian disease, y = 0.88x -  
3.9; ovarian cancer, y ~ 0.72 x + 19).
entire group of healthy controls (0.80, Fig. 2A) and the 
patients with ovarian cancer (0.72, Fig. 2C) or benign 
ovarian diseases having CA 125 concentrations >100 
kAU/L (0.88, Fig. 2C), Increased regression slopes were 
observed for the subsets with CA 125 values up to 100 
kAU/L (Fig. 2A, 2B) for samples from women with 
ovarian cancer (1.67 and 2.45) or benign ovarian dis­
eases (1.50 and 3.37).
Interference of HAMA. Prior to intravenous injection 
of radiolabeled OC 125 F(ab')2 fragments into three 
subjects, no relevant differences were observed be­
tween CA 125 measurements with the two assays
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Table 2. Comparison of CA 125 concentrations (kAU/L) 
determined by IMx and RIA in serum of three patients
treated with OC 125 F(ab')2.
Preinjection Postinjection
Patient HAMA" RIA IMx Week HAMA RIA IMx
1 <28 300 200 2 1100 750 350
3 1700 >5000 16
2 <28 7.8 4.8 3 25000 68000 71
6 27000 44000 46
3 <28 43 40 4 1500 2300 160
6 5600 5000 150
° HAMA were quantified with a homologous double-determinant OC 125 
F(ab')2 assay expressing HAMA concentrations (kAU/L) in terms of CA 125 
calibrator material.
(Table 2). Between 2 and 6 weeks postinjection, HAMA 
serum concentrations increased dramatically to 1100- 
27 000 kAU/L concomitantly with substantial in­
creases of CA 125 concentrations with either assay 
procedure. RIA values were always substantially 
higher than IMx values.
Clinical Evaluation
Healthy controls. The CA 125 concentrations ob­tained with the IMx in the serum specimens from 124 
perimenopausal women with echoscopically normal 
ovaries were invariably ¿35 kAU/L. With the CA 125 
RIA procedure, only two sera exceeded this concentra­
tion (43 and 44 kAU/L, Table 3). Of all sera, 24 had CA 
125 RIA values ¿7.0 kAU/L and were thus excluded 
from the method comparison depicted in Pig. 2. Of the
124 sera, 63 (51%) yielded CA 125 IMx concentrations 
below the detection limit of the RIA (¿7.0 kAU/L), and 
16 of these sera had values ¿3.5 kAU/L (data not 
shown). The CA 125 values of 95% of all controls were 
¿30 kAU/L by RIA, compared with 23 kAU/L by IMx.
Benign ovarian and other benign disease. The max­
imum CA 125 serum concentration observed in this 
group was 760 kAU/L as determined by IMx, and 810 
kAU/L by RIA. The positivity rate of CA 125 (propor­
tion of CA 125 values >35 kAU/L) yielded by the IMx 
procedure was 30%, and 27% in the case of RIA 
measurements. The sera from other benign diseases 
did not show differences between positivity rates with 
both assays (Table 3).
Ovarian carcinoma. In patients with malignant ep­
ithelial tumors of the ovary we used the CA 125 IMx to 
assay sera collected before primary treatment (Table 3) 
or during clinical follow-up (Table 4). Differences be­
tween the distributions of CA 125 IMx or RIA values of 
all FIGO stages were tested with two-sided Student’s 
¿-tests of the logarithmic CA 125 values and were in all 
cases highly significant (P <0.001).
Follow-up studies of CA 125 serum concentrations as 
determined with the two assays demonstrated almost 
identical linear regression slopes for individual pa­
tients, with ranges from 0.612 to 0.952 (Table 4). The 
mean value of the slopes (0.736) did not differ from the 
slope calculated from the determinations performed on
Table 3. Comparison of IMx CA 125 assay and CA 125
RIA for controls and patients.
CA 125, kAU/L
Subjects (and no.) Assay Median Range >35, % >65, ‘
Controlsa (124) RIA 11 <7.0-44 2 0
IMx 7.0 0.8-35 0 0
Benign diseases
Ovary (60) RIA 21 <7.0-810 27 12
IMx 20 4.3—760 30 18
Other gynecol, (31) RIA 10 <7.0-30 0 0
IMx 8.1 2.6-31 0 0
Nongynecol. (Gl; 33) RIA 8.8 <7.0-290 18 12
IMx 11 1.0—210 18 9
Malignancies
Ovary
FIGO stage I (38) RIA 27 <7.0-390 26 24
IMx 33 5.2-320 42 21
FIGO stage II (7) RIA 140 17-4300 86 71
IMx 170 25-3400 86 71
FIGO stage III (40) RIA 1800 8.9-23 000 95 88
IMx 1200 7.2-14 000 98 88
FIGO stage IV (19) RIA 2600 120-10 000 100 100
IMx 1700 100-7700 100 100
All FIGO stages (104) RIA 250 <7.0-23 000 70 65
IMx 260 5.2-14 000 80 67
Other gynecol. (81) RIA 15 <7.0-2000 20 10
IMx 12 0.6—1300 20 10
Nongynecol. (Gl; 112) RIA 15 10—490 22 15
IMx 12 2.7-400 21 13
B Perimenopausal women with echoscopically checked normal ovaries. 
Gl, gastrointestinal.
the 61 serum specimens with CA 125 values >100 
kAU/L and collected from pretreatment patients with 
ovarian carcinoma (Fig. 2C).
Other malignant diseases. No remarkable differ­
ences were observed between the respective positivity 
rates obtained for blood samples collected from the 
pretreatment patients with other gynecologic and non- 
gynecologic malignancies (Table 3).
Table 4. Follow-up of eight ovarian cancer patients
with the Abbott IMx CA 125 assay.
Serum
CA 125, Linear regression analysis
No. of kAU/L,
specimens" range Slope Intercept Sylx r
6 14-89 0.703 -1.32 1 0.999
10 92-2800 0.744 -5.69 58 0.998
8 8-3800 0.704 + 12.6 170 0.986
10 10-240 0.612 -0.21 11 0.984
11 7-530 0.952 +1.69 7 0.998
8 15-4400 0.690 +21.0 40 0.999
5 90-1900 0.671 +33.0 41 0.998
13 8-1800 0.808 +1.49 5 0.999
Mean 0.736 +9.24 0.995
fl Per patient, total number of samples above minimum detectable concen­
tration with Abbott CA 125 RIA (i.e., >7.0 kAU/L). 
b y = IMx, x = RIA.
214 CLINICAL CHEMISTRY, Vol. 41, No. 2, 1995
CA-125 Assay Systems
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vs RIA if either healthy women (slope <1.0) or those with 
ovarian disorders (with slopes >1.0 for both benign and 
malignant diseases) are evaluated. This means that CA
>125 IMx values are higher than RIA in cases of ovarian 
disorders, whereas IMx values are lower than those 
measured by RIA in perimenopausal controls who have 
normal or diminished ovarian activity. The diversities in 
CA 125 measurements obtained with IMx and RIA con­
firm the observations on the calculated AUCs of the 
constructed ROC curves, which are similar for the respec­
tive ROC curves of benign vs malignant ovarian disease 
(Fig. 3B) and different (AUCxm* > AUCria) for ROC 
curves of healthy perimenopausal controls vs patients with ovarian cancer (Fig. 3A).
The clinical evaluation of the IMx CA 125 assay 
demonstrated better specificity and sensitivity than 
the CA 125 RIA. At the internationally accepted CA 
125 cutoff value of 35 kAU/L, FIGO stage I ovarian 
cancers were positive in 42% of cases with CA 125 IMx, 
but only 26% were positive by RIA—a gain of 16% in 
favor of the IMx assay. The positivity rates of both 
assays were similar (86%) for FIGO stage II ovarian 
cancers. The 99% CA 125 cutoff concentrations, i.e., the
CA 125 value of the 122nd ranked sample, for the 124
thealthy perimenopausal women tested were 29 kAU/L 
with the IMx and 32 kAU/L by RIA. Above these 
cutoffs, ovarian cancers (FIGO stage I) were positive in 
58% of cases with the IMx assay, and 39% with the 
RIA. Compared with positivities measured at 35 
kAU/L, the respective gains in positivity at these lower 
cutoff values were 16% in case of IMx and 13% with 
ROC analysis. Fig. 3 represents the ROC curves and RIA. The lower serum cutoff figures of our control 
the corresponding AUCs for the two CA 125 immuno- group than those of apparently healthy blood donors 
assay procedures. The AUCs of both IMx and RIA reported by others (3,17) may result from the strict 
procedure are >0.90 if specificity is based on the group selection criteria of the reference group used in the 
of healthy control women (Fig. 3A), but are much lower present study. All the perimenopausal women in our
CA-125 Assay Systems
IMx, AUC= 0.829 
RIA, AUC* 0.826
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i
Fig. 3. ROC curves of CA 125 IMx and RIA for cases of ovarian 
cancer (n = 104) vs (A) perimenopausal women (n = 124) and vs (ß) 
those with benign ovarian disease (n = 60).
(AUCIM x 0.829; AUCRIA = 0.826) if we use the group reference group had passed a careful ultrasound exam-of women with benign ovarian disorders for reference ination of their ovaries. The ROC curves for this control
(Fig. 3B). group indeed appear to have greater
Discussion
groups
IMx
Recently suggested guidelinesare: 0.5-Q.7,curves
improvedcalibrators. This has provided better agreement 
values with other test methods such as Abbott e 
Centocor CA 125 RIA (15, 16). Comparison
low accuracy; 0.7-0.9, accuracies useful for some pur­
poses; and >0.9, high accuracy (18, 19). Thus, as a 
quantitative measure of accuracy, the AUC of the IMx 
CA 125 assav of 0.971 means the IMx mav be more
assay procedures (Fig. 2) demonstrated a systematic useful than the RIA (AUC = 0.932) for further studies
overestimation on screening of populations at risk for early ovarianregression slope for CA 125 RIA values >7.0 kAU/L cancer as recently reviewed by Bast (20) and others
serum specimens from healthy perim (21, 22). However, evaluations of the available screen-
women 100) and 0.72 for the ovarian ing studies on ovarian cancer have suggested that, if(n = CA 125 is the only criterion, screening of a generalkAU/L
recommended61) as well as those during follow-up of their recurrent (asymptomatic) populationdiseases. The latter slope becomes substantially a single occasion cannot bsteeper, i.e., 1.67 and 2.45, if only CA 125 values ¿100 sidérations of costs and false-positive rates (20-22)
kAU/L are considered. This is in line with the calcu- because many factors other than cancer can lead to
lated slopes of 1.50 and 3.37 for the patients with modest
benign ovarian diseases whose CA 125 serum pregnancy, benign gynecologic and pelvic infiamma
were 7.0 and >35-100 kAU/L More
observe discrepancies between the slopes for CA 125 IMx same group of asymptomatic
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125 alone cannot discriminate between benign and malignant conditions of the ovary, although another 
study suggests that urinary gonadotropin fragment 
may provide the necessary additional information (23). 
Conversely, in women with symptoms of pelvic mass 
disorders, the much lower but equal AUCs for IMx and 
RIA (0.83, Fig. 3B) obtained with the group of benign 
ovarian diseases as controls suggest a similar perfor­
mance of the two assay procedures, despite a report 
(20) that quantification of CA 125 is adequate for 
discriminating malignant from benign pelvic masses in 
postmenopausal women.
Another change made in the improved IMx CA 125 
assay concerned the increased protein concentration of the specimen diluent buffer. This has been reported to 
improve dilution linearity (15), although we still ob­
served nonlinear responses at higher dilutions (Table 
1). Thus, the diluent buffer needs further improvement 
to overcome this matrix effect.
The improved IMx CA 125 test demonstrates an 
outstanding precision profile across the entire dynamic 
range and particularly in the very low concentration 
range. Consequently, if one decides to assay a serum specimen only once, the IMx assay is obviously the 
most suited candidate. The high precision obtained 
with the IMx MEIA system is probably due to the use 
of a closed system, because only reagents developed 
specifically for the instrument are applicable, with very 
strict test procedures. Another possibility for increased 
precision with the IMx kit may be the additional 
inclusion of a polyclonal anti-CA 125 serum as the 
capture antibody. Such an antibody may have an 
higher affinity for the CA 125 antigen than the mono­
clonal OC 125 used as signal antibody in the IMx assay 
and as both capture and signal antibody in the other 
CA 125 assay procedures.
We thank the laboratory staff for expert technical assistance, and Ingeborg Bertschi, Abbott GmbH Diagnostika, Wiesbaden, Germany, for providing the IMx diagnostic testing kits and scientific support.
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